FI113655B - 2,7-aryylisubstituoituja oktahydro-1H-pyrido[1,2-a]pyratsiinijohdannaisia - Google Patents

2,7-aryylisubstituoituja oktahydro-1H-pyrido[1,2-a]pyratsiinijohdannaisia Download PDF

Info

Publication number
FI113655B
FI113655B FI971310A FI971310A FI113655B FI 113655 B FI113655 B FI 113655B FI 971310 A FI971310 A FI 971310A FI 971310 A FI971310 A FI 971310A FI 113655 B FI113655 B FI 113655B
Authority
FI
Finland
Prior art keywords
pyrido
octahydro
pyrazine
methyl
fluoropyrimidin
Prior art date
Application number
FI971310A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971310A0 (fi
FI971310A (fi
Inventor
Kishor Amratlal Desai
Anton F Fliri
Mark A Sanner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI971310A0 publication Critical patent/FI971310A0/fi
Publication of FI971310A publication Critical patent/FI971310A/fi
Application granted granted Critical
Publication of FI113655B publication Critical patent/FI113655B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI971310A 1994-09-30 1997-03-27 2,7-aryylisubstituoituja oktahydro-1H-pyrido[1,2-a]pyratsiinijohdannaisia FI113655B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31547094A 1994-09-30 1994-09-30
US31547094 1994-09-30
IB9500689 1995-08-24
PCT/IB1995/000689 WO1996010571A1 (fr) 1994-09-30 1995-08-24 Derives d'octahydro 1-h-pyrido[1,2-a] pyrazine substituee en 2,7

Publications (3)

Publication Number Publication Date
FI971310A0 FI971310A0 (fi) 1997-03-27
FI971310A FI971310A (fi) 1997-03-27
FI113655B true FI113655B (fi) 2004-05-31

Family

ID=23224581

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971310A FI113655B (fi) 1994-09-30 1997-03-27 2,7-aryylisubstituoituja oktahydro-1H-pyrido[1,2-a]pyratsiinijohdannaisia

Country Status (34)

Country Link
US (1) US5852031A (fr)
EP (1) EP0783503B1 (fr)
JP (1) JP3287574B2 (fr)
KR (1) KR100244848B1 (fr)
CN (1) CN1068327C (fr)
AT (1) ATE209648T1 (fr)
AU (1) AU681310B2 (fr)
BR (1) BR9504230A (fr)
CA (1) CA2200959C (fr)
CO (1) CO4410335A1 (fr)
CZ (1) CZ285090B6 (fr)
DE (1) DE69524241T2 (fr)
DK (1) DK0783503T3 (fr)
ES (1) ES2166830T3 (fr)
FI (1) FI113655B (fr)
HR (1) HRP950507B1 (fr)
HU (1) HUT77354A (fr)
IL (1) IL115384A (fr)
MX (1) MX9702350A (fr)
MY (1) MY113729A (fr)
NO (1) NO308995B1 (fr)
NZ (1) NZ290936A (fr)
PE (1) PE47196A1 (fr)
PL (1) PL180899B1 (fr)
PT (1) PT783503E (fr)
RU (1) RU2163239C2 (fr)
SI (1) SI9520096A (fr)
SK (1) SK284341B6 (fr)
TR (1) TR199501194A2 (fr)
TW (1) TW406081B (fr)
UA (1) UA50720C2 (fr)
WO (1) WO1996010571A1 (fr)
YU (1) YU63795A (fr)
ZA (1) ZA958223B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
DE69615404T2 (de) * 1995-12-21 2002-06-06 Pfizer 2,7-SUBSTITUIERTE OCTAHYDROPYRROLO(1,2-a)PYRAZINDERIVATE
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
EP0953567A3 (fr) * 1998-04-29 2003-04-02 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
GT199900060A (es) * 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) * 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
EP1177792A3 (fr) * 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
US6670476B2 (en) 2000-11-29 2003-12-30 Pfizer Inc. Resolution of trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido[1,2-a]pyrazine
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4517187A (en) * 1982-10-18 1985-05-14 Pennwalt Corporation 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants
DE3564683D1 (en) * 1984-08-07 1988-10-06 Cortial 4-(arylpiperazinylethylaminoethoxy) phenol derivatives, process for their preparation and their therapeutical application
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
IT1204803B (it) * 1986-02-17 1989-03-10 Acraf Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono,procedimento per prepararlo e intermedio utile in detto procedimento
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
WO1990008148A1 (fr) * 1989-01-23 1990-07-26 Pfizer Inc. Agents anxiolytiques bis-aza-bicycliques
EP0569387B1 (fr) * 1991-01-31 1995-04-05 Pfizer Inc. Decomposition de trans-2-(2-pyrimidinyle)-7-(hydroxymethyle)octahydro-2h-pyrido 1,2-a]pyrazine
CA2101252C (fr) * 1991-02-27 1998-02-17 Frank J. Urban Methode de preparation de trans-piperidine-2,5-dicarboxylates
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
US5185449A (en) * 1991-02-27 1993-02-09 Pfizer Inc. Process and intermediate for certain bis-aza-bicyclic anxiolytic agents
US5565453A (en) * 1991-09-25 1996-10-15 Pfizer Inc. Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines
US5719286A (en) * 1992-06-16 1998-02-17 Pfizer Inc. Process and intermediates for bis-aza-bicyclic anxiolytic agents
US5670522A (en) * 1992-10-23 1997-09-23 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
WO1994010145A1 (fr) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Ligands pour les sous-types de recepteurs de dopamine
SK106395A3 (en) * 1993-03-01 1995-12-06 Merck Sharp & Dohme Treating and treatment or prevention of mental diseases
US5576319A (en) * 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
JPH09500357A (ja) * 1993-03-01 1997-01-14 メルク シヤープ エンド ドーム リミテツド ピロロ−ピリジン誘導体
WO1994020471A1 (fr) * 1993-03-05 1994-09-15 Merck Sharp & Dohme Limited Derives de la quinolone comme ligands des recepteurs d4 de la dopamine
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
PT783503E (pt) 2002-03-28
UA50720C2 (uk) 2002-11-15
JP3287574B2 (ja) 2002-06-04
ES2166830T3 (es) 2002-05-01
AU3189395A (en) 1996-04-26
HRP950507A2 (en) 1997-08-31
NO308995B1 (no) 2000-11-27
ZA958223B (en) 1997-04-01
CZ285090B6 (cs) 1999-05-12
US5852031A (en) 1998-12-22
KR970706282A (ko) 1997-11-03
NZ290936A (en) 1998-01-26
JPH09511527A (ja) 1997-11-18
KR100244848B1 (ko) 2000-03-02
CA2200959C (fr) 2000-05-23
HUT77354A (hu) 1998-03-30
EP0783503A1 (fr) 1997-07-16
MY113729A (en) 2002-05-31
DK0783503T3 (da) 2002-02-11
CN1068327C (zh) 2001-07-11
CN1168672A (zh) 1997-12-24
EP0783503B1 (fr) 2001-11-28
PL319636A1 (en) 1997-08-18
CO4410335A1 (es) 1997-01-09
DE69524241D1 (de) 2002-01-10
TR199501194A2 (tr) 1996-06-21
BR9504230A (pt) 1996-08-06
SK32597A3 (en) 1998-09-09
FI971310A0 (fi) 1997-03-27
FI971310A (fi) 1997-03-27
IL115384A0 (en) 1995-12-31
SI9520096A (sl) 1998-04-30
SK284341B6 (sk) 2005-02-04
NO971416L (no) 1997-05-20
DE69524241T2 (de) 2002-06-13
PE47196A1 (es) 1996-11-11
CA2200959A1 (fr) 1996-04-11
HRP950507B1 (en) 2002-06-30
AU681310B2 (en) 1997-08-21
WO1996010571A1 (fr) 1996-04-11
RU2163239C2 (ru) 2001-02-20
YU63795A (sh) 1999-03-04
CZ94797A3 (cs) 1998-07-15
NO971416D0 (no) 1997-03-25
ATE209648T1 (de) 2001-12-15
IL115384A (en) 1999-10-28
TW406081B (en) 2000-09-21
PL180899B1 (pl) 2001-04-30
MX9702350A (es) 1997-06-28

Similar Documents

Publication Publication Date Title
CA2822003C (fr) Imidazopyridines en tant qu'agents antiviraux contre le virus respiratoire syncytial
EP2225227B1 (fr) 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones et 1,3-dihydrospiro[inden-2,3']-pyrroles en tant qu'antagonistes de CGRP
EP2443092B1 (fr) Composes bicycliques et tricycliques utilises en tant qu'inhibiteurs de kat ii
TW200817411A (en) Pyrimidine derivative as PI3 inhibitor and use thereof
NO176356B (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser
EP0765320B1 (fr) Derives de la benzimidazolone a activite dopaminergique centrale
US20080085884A1 (en) Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones
FI113655B (fi) 2,7-aryylisubstituoituja oktahydro-1H-pyrido[1,2-a]pyratsiinijohdannaisia
AU775093B2 (en) 2,7-substituted octahydro-1H-pyrido(1,2-a)pyrazine derivatives as ligands for serotonin receptors
EP2437601A1 (fr) Bis-pyridylpyridones à usage d'antagonistes de récepteur d'hormone concentrant la mélanine 1
NZ579766A (en) Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
US20120077795A1 (en) Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
NO309936B1 (no) 2,7-Substituerte oktahydro-pyrrol[1,2-a]pyrazin-derivater, anvendelse derav, farmasøytisk preparat, samt mellomprodukter for fremstilling av derivatene
EP0115920A2 (fr) Dérivés de pyrazino(2',3'-3,4)pyrido(1,2-A)indole
AU2022253074A1 (en) Taar1 and serotonin modulators, and pharmaceutical compositions, and methods of use thereof
JP2020519694A (ja) オレキシン受容体アンタゴニス
MXPA00006403A (en) 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives

Legal Events

Date Code Title Description
MA Patent expired